https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0r=
CyBv9bezcPT-2BuItTLKIHepbxTbo-2FYbVFPSBekB-2Bmk9X7Kl8shoTE6BsSbYYjHYcOVCrOC=
rjYrJUHPDVbu1NKaBE-3DhKKA_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2=
FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLN=
n-2B6FohpNoV333ZtNhorLky6z7879AXAcg1LofBiyvC5j2J1KlmycSfC-2FYVaxRY8jPqKnPWR=
QywHmnf3RHbTe2B7FTHwvZmqOIosUflhU1XHDpap0x1oV1KsBHQ91mmOxCUxjevl6Pxp4g3U4wO=
eVP2nt8DDkTdVt-2Fh5IUfU8XWbvWZI6QfVxS71B2y4Oh9P-2FgQW8aG6oAv6WY-2FFGUeUWpbG=
JrJyJVKpObpaOfltahdyYcFe0IZzcFqg-3D
** Acquisition of own shares
------------------------------------------------------------
Brussels (Belgium), 26 April 2024 =E2=80=93 20:00 (CEST) =E2=80=93 Regulate=
d information=C2=A0
In accordance with article 8:4 of the Royal Decree of 29 April 2019 executi=
ng the Belgian Code on Companies and Associations, UCB SA/NV (=E2=80=9CUCB=
=E2=80=9D or the =E2=80=9CCompany) (Euronext Brussels: UCB) hereby disclose=
s certain information in relation to its Share Repurchase Program 2024.=C2=
=A0
Under this program, UCB has requested a financial intermediary to repurchas=
e up to 1,300,000 UCB shares on its behalf under the terms of a discretiona=
ry mandate agreement with initial validity until 30 June 2024, effective as=
from 02 April 2024, to cover current and future obligations under UCB's Lo=
ng Term Incentive Plans for its personnel.
In the framework of this Share Repurchase Program 2024, UCB repurchased 15.=
994 UCB shares on Euronext Brussels in the period from 19 April 2024 up to =
and including 26 April 2024. No purchase of own shares was made in the peri=
od from 22 April up to and including 26 April 2024, in the framework of the=
organization of UCB=E2=80=99s Annual General Meeting.
https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0r=
CyBv9bezcPT-2BuItTLKIHepZDUN4KZf5FcFfoSVl2v2mQY-2BAp6qtKdwUd4iRvMKOx1lpU1XX=
uaIQ0cC40rMNm572WyEmxIVrN21eapAEKwDOfggwH_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFG=
M-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8=
cV3s33SbkEZvEGLNn-2B6FohpNoV333ZtNhorLky6z7879AXAcg1LofBiyvC5j2J1KlmycSfC-2=
FYVaxRY8jPqKnPWRQywHmnf3RHbTe2B7FTHwvZmqOIuWKsNUH4YjZ-2B5vrXnIr7MjG1YWX3ntC=
tG7he-2B4WEIxZZFSJrcpKYzLcNyqV2tMzKxYLN7LmWjaSGEvxLj2ePEGyga-2Fvjuv3UGlDx25=
T3pQ-2BRBYJDZKFAe9UNuIW3rDEjPt13cl5VtvCvMKiBidILao-3D
This press release is available on UCB SA/NV=E2=80=99s website via the foll=
owing link (https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUz=
lo7XKIuSly0rC4Oa12rFuiaXNgb0F6L7ybSCidGRlUFwTxzrkzCt6dOMzdZPcjqPbg8jratFLJj=
fTg-3D-3DLt3D_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BI=
fez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV=
333ZtNhorLky6z7879AXAcg1LofBiyvC5j2J1KlmycSfC-2FYVaxRY8jPqKnPWRQywHmnf3RHbT=
e2B7FTHwvZmqOIo6MlsdQ71TPAIgYWZsQCYMRM2MlboFrq-2BT-2F6vN2gCWmS2g2m0rvf6yxas=
mlJ4-2B2I6kv4U4UBNkmHVffRLJzLoHP6Wgo14rv2fRlwZtuU-2Fpv2aUX1jlkXPQ9kneqEPO-2=
FB9pe2N-2FiVRk63p2jGxsra4E-3D .
For further information, contact UCB:=C2=A0
Investor Relations
Antje Witte=C2=A0
T +32 2 559 94 14
Antje.Witte@ucb.com
Corporate Communications
Laurent Schots=C2=A0
T+32 2 559 92 64
laurent.schots@ucb.com =C2=A0=C2=A0 =C2=A0
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 9,000 peopl=
e in approximately 40 countries, the company generated revenue of =E2=82=AC=
5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Foll=
ow us on Twitter: @UCB_news.
=C2=A0
GenericFile
240426 - Acquisition of own shares ENG (https://u7061146.ct.sendgrid.net/ls=
/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepZDUN4KZf5Fc=
FfoSVl2v2mQIwK7Mvsc9w4E1VsHHXKgsC20tQaPQHwiiWmMSxYJZpc-3DhsZ8_2dCLUNbuBjhX7=
46-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd=
4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV333ZtNhorLky6z7879AXAcg1Lof=
BiyvC5j2J1KlmycSfC-2FYVaxRY8jPqKnPWRQywHmnf3RHbTe2B7FTHwvZmqOIpT5APS-2BUNUX=
IIhCuV3CUJ3EbdVhW8UJcRFG0AIYxOyNXIkJeRoMWEwkSXlUTMTkAGxVUSFMHFYCOQk7mP4G4xL=
-2Fy2zbTFdD7pkI2df-2FQurR5npKPW9hZX7-2Bd6WfSp14gnFCwv76ArJ-2F39ro2XzFjWo-3D=
GenericFile
240426 - Verwerving van eigen aandelen NL (https://u7061146.ct.sendgrid.net=
/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepZDUN4KZf=
5FcFfoSVl2v2mQ-2BhH4HTmK769LGY-2BT3E-2FATZ-2BmfD2RLURTxOqKPJ7u-2B5c-3DjtL9_=
2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mp=
lcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV333ZtNhorLky6z=
7879AXAcg1LofBiyvC5j2J1KlmycSfC-2FYVaxRY8jPqKnPWRQywHmnf3RHbTe2B7FTHwvZmqOI=
m-2FlN-2B94p4MC5glah83X9f64UnkIa8uajHJN4WZqDoyR0aezzMW63rj0Icgu4-2FdN7WhtWz=
6MxFEpJLBDn8ZSbNdaPE6pSCRmGBG3E1W-2BTm5cqs5CmgCo38IArKNzPXfDLe6CbeJ9EfIQngN=
0GdKzggQ-3D GenericFile
240426 - Acquisition actions propres FR Draft 002 (https://u7061146.ct.send=
grid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHep=
ZDUN4KZf5FcFfoSVl2v2mQcG22YYwqkjwVi5A7t8RYsfakrpSypH2zYJHTIUYKdnI-3DKPIV_2d=
CLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplc=
EW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV333ZtNhorLky6z78=
79AXAcg1LofBiyvC5j2J1KlmycSfC-2FYVaxRY8jPqKnPWRQywHmnf3RHbTe2B7FTHwvZmqOIu2=
x-2BeyWG1xXmAq10QbvhroGuwdr1aiTgNhnpD96SUHvyotRQXwN6BW3UsrBir2-2B6cXPROqhqY=
9a3wxTxF1dxVQsUpHK0pGxKDeuhfxBaC2H5znk4EYhbA5eTdnbZAQB1p8XwhRJNyeEopwNTFnlD=
yM-3D Image
Chart 1 April 26 2024 ENG (https://u7061146.ct.sendgrid.net/ls/click?upn=3D=
u001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepZDUN4KZf5FcFfoSVl2v2mQY-=
2BAp6qtKdwUd4iRvMKOx1tT1gDxlp2mFnyXT1HNMwgw-3DV44j_2dCLUNbuBjhX746-2FvM63L9=
Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO=
93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV333ZtNhorLky6z7879AXAcg1LofBiyvC5j2J1K=
lmycSfC-2FYVaxRY8jPqKnPWRQywHmnf3RHbTe2B7FTHwvZmqOIvCntXbT0e0-2Bry8boQIQecP=
DTzqbq7GtoNBLJU9YH1rD-2BWxYcKSXVW7kMlCb3IUQUnaVn0dW2ltFpwdIsrAqAxbHckWePGNT=
Ed8OMebRZnS6o0ouPhYRmnK982q5xLEDdDje30oheGhAmh873EdTh5I-3D
______________________
If you would rather not receive future communications from UCB SA, please g=
o to https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIu=
Sly0rC3nfmD42E6tJ6HwHGmqtXbhtXDlQ2cTEdRpWV-2BrYPIUNlOYgMRxA6-2BpVOoZl6QBhbJ=
ERDGVuWFaxpPa7x3pIiRoTWw9NPQ7ypmmdjQJ7HuOtGXjnD4Jn9iVs5YMktmCY9begWkqkiXt-2=
FxF5uZ8JKwNQ-3DOItG_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2=
nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6F=
ohpNoV333ZtNhorLky6z7879AXAcg1LofBiyvC5j2J1KlmycSfC-2FYVaxRY8jPqKnPWRQywHmn=
f3RHbTe2B7FTHwvZmqOIuPb1TVn3fQC3arm2tby-2FhMtTJSG8v2I5DQ61dafOCUETnTKd-2FnX=
4ZcBUv4gD8EUW688xynBdtYN3UwlGxfrEA0SPa5DgATqQV5kwTtZuA4ye1CXgAclro0oEaUMx2a=
QjcgZiE-2B3DhHZoQSMjAnlNHA-3D
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium
